Laboratory of Cancer GeneticsThe Laboratory of Cancer Genetics (LCG), one of the basic research laboratories in the Department of Clinical Oncology, was established in 1999. The vision and mission of LCG is to explore the molecular mechanisms involving in the development and progression of cancers, especially the effects of genetic alterations, cancer stem cells (CSCs) and tumor microenvironment (TME) in liver, esophageal and nasopharyngeal cancers. During the last 20 years, our major scientific contributions include: (1) identified and characterized many important cancer-related genes, such as EIF-5A2, CHD1L, SEI-1 and SPOCK1 in liver and esophageal cancers; (2) discovered several cancer stem cell-related markers (CD133 and CD90) and genes (ATOH8, MAEL and Integrin a7) in liver and esophageal cancer; (3) discovered the role of RNA editing in cancer development and progression. Our research work has been supported by the Hong Kong Government (RGC GRF, RGC CRF, RGC TBRS, ITF, NSFC/RGC Joint Research Scheme, HMRF, UGC AoE), Sophie YM Chan Professor of Cancer Research, Collaborative Research Fund from industry (New B Innovation, Pfizer, CytoTrend), and private donations (Leung Kwok Tze Research Fund, Tessy Cheng Grove Research Fund, and Professor Jonathan Sham Research Fund).
Laboratory of Cancer Molecular GenomicsThe Laboratory of Cancer Molecular Genomics (LCMG), one of the basic research laboratories in the Department of Clinical Oncology, was established in 2009. The vision and mission of LCMG is to focus on elucidating the molecular genetic basis of two cancers of great concern to the Chinese population, namely nasopharyngeal carcinoma (NPC) and esophageal carcinoma (ESC).
Imaging and Blood Biomarker Group
The Imaging and Blood Biomarker Group (IBBG), started in 2018, is missioned to improve cancer cure through conducting patient centered research including clinical trial and translational outcome correlative science. With a focus on n Imaging and Blood Biomarkers which are readily available for every cancer patient, our research will build big data on the full spectrum of patient characteristics, in-depth tumor features, host immune responses, treatment detail and treatment responses, and use the most advanced technology such as Single Cell Genomic, Bioinformatics and Artificial Intelligence (AI) to understand the mechanism and build predictive models for treatment outcome including tumor control, cancer cure, treatment toxicity and quality of life. The group envision near future realization of AI models for treatment outcome prediction in hundreds thousands cancer patients which may guide Precision Oncology to a new height of success.
The group welcomes collaborations with researchers from multidisciplinary medicine and scientists across wide spectrum of scientific fields to advance Precision Oncology. Together, we can be stronger in fighting the life threatening Cancers.